Bayesian framework for multi-source data integration-Application to human extrapolation from preclinical studies

被引:0
作者
Boulet, Sandrine [1 ,2 ]
Ursino, Moreno [1 ,2 ,3 ]
Michelet, Robin [4 ]
Aulin, Linda B. S. [4 ]
Kloft, Charlotte [4 ]
Comets, Emmanuelle [5 ,6 ]
Zohar, Sarah [1 ,2 ,7 ]
机构
[1] Inria, HeKA, Paris, France
[2] Univ Paris Cite, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France
[3] AP HP, Assistance Publ Hop Paris, Unit Clin Epidemiol, INSERM,CIC EC 1426, F-75019 Paris, France
[4] Inst Pharm, Dept Clin Pharm & Biochem, Freie Universitaet Berlin, Berlin, Germany
[5] Univ Rennes, Irset Inst Rech Sante Environm & Travail, INSERM, EHESP,UMRS 1085, Rennes, France
[6] Univ Paris Cite, INSERM, IAME, Paris, France
[7] Inria, Equipe HeKA, INSERM, PariSante Campus,10 Rue Oradour Sur Glane, F-75015 Paris, France
关键词
Commensurability; Hellinger distance; posteriors conflict; posteriors merging; translational; INHIBITOR LY2157299 MONOHYDRATE; CLINICAL-TRIALS; MODEL; SIZE;
D O I
10.1177/09622802241231493
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In preclinical investigations, for example, in in vitro, in vivo, and in silico studies, the pharmacokinetic, pharmacodynamic, and toxicological characteristics of a drug are evaluated before advancing to first-in-man trial. Usually, each study is analyzed independently and the human dose range does not leverage the knowledge gained from all studies. Taking into account all preclinical data through inferential procedures can be particularly interesting in obtaining a more precise and reliable starting dose and dose range. Our objective is to propose a Bayesian framework for multi-source data integration, customizable, and tailored to the specific research question. We focused on preclinical results extrapolated to humans, which allowed us to predict the quantities of interest (e.g. maximum tolerated dose, etc.) in humans. We build an approach, divided into four steps, based on a sequential parameter estimation for each study, extrapolation to human, commensurability checking between posterior distributions and final information merging to increase the precision of estimation. The new framework is evaluated via an extensive simulation study, based on a real-life example in oncology. Our approach allows us to better use all the information compared to a standard framework, reducing uncertainty in the predictions and potentially leading to a more efficient dose selection.
引用
收藏
页码:574 / 588
页数:15
相关论文
共 25 条
  • [1] The scale transformed power prior for use with historical data from a different outcome model
    Alt, Ethan M.
    Nifong, Brady
    Chen, Xinxin
    Psioda, Matthew A.
    Ibrahim, Joseph G.
    [J]. STATISTICS IN MEDICINE, 2023, 42 (01) : 1 - 14
  • [2] [Anonymous], 2005, GUIDANCE IND ESTIMAT
  • [3] Betancourt M, 2018, CONCEPTUAL INTRO HAM, DOI DOI 10.48550/ARXIV.1701.02434
  • [4] Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
    Bueno, Lorea
    de Alwis, Dinesh P.
    Pitou, Celine
    Yingling, Jonathan
    Lahn, Michael
    Glatt, Sophie
    Troconiz, Inaki F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 142 - 150
  • [5] Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
    Duputel, Benjamin
    Stallard, Nigel
    Montestruc, Francois
    Zohar, Sarah
    Ursino, Moreno
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2023, 32 (05) : 963 - 977
  • [6] EMA, 2017, Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials with Investigational Medicinal Products
  • [7] Gelman Andrew, 1992, Stat. Sci., P457, DOI [DOI 10.1214/SS/1177011136, 10.1214/ss/1177011136]
  • [8] Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
    Gueorguieva, Ivelina
    Cleverly, Ann L.
    Stauber, Anja
    Pillay, N. Sada
    Rodon, Jordi A.
    Miles, Colin P.
    Yingling, Jonathan M.
    Lahn, Michael M.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (05) : 796 - 807
  • [9] La Gamba F., 1941, PHARM STAT PAGE PST, V2019
  • [10] Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology
    Lestini, Giulia
    Dumont, Cyrielle
    Mentre, France
    [J]. PHARMACEUTICAL RESEARCH, 2015, 32 (10) : 3159 - 3169